Small molecule · Agonist of aryl hydrocarbon receptor (AHR) · developed by Organon Llc
Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist. It acts on the aryl hydrocarbon receptor, a transcription factor, and is used in the treatment of plaque psoriasis and atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 28, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05789576 | Phase 4 | Psoriasis | Completed | OGN |
| NCT05680740 | Phase 4 | Psoriasis | Completed | OGN |
| NCT03983980 | Phase 3 | Plaque Psoriasis | Completed | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Plaque PsoriasisPsoriasis
Updated Nov 15, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →